AKBA Akebia Therapeutics Inc.

$AKBA GM and Happy Friday! It's that time so here you go! Feel free to ask if you would like to see anything else. Heading in the right direction this time! GL folks.

$AKBA Big changes afoot at Fresenius Fresenius Medical Care as it is abruptly replacing current CEO Helen Giza with new CEO Shervin J. Korangy effective this Monday Oct 12th. If I remember correctly the new CMO took over on jan 1, 2026. So the 2 most powerful positions for a biotech has changed hands in less than a year. Maybe now they can be more open to using Vafseo at their clinics and be more forward thinking. I estimate at least $800 mm in cost savings per year (roughly 7% of its market cap) for Fresenius if they simply use Vafseo over their ESAs just due to less hospitalization rates for their DD anemic patients. Fresenius market cap is now even LOWER than Davita at $11 bb, what a shocking change that was, and its stock price is like 8x smaller vs Davita. It is time for them to move on from ESAs and head towards Vafseo. Good luck to their new CEO.

$AKBA tomorrow is the big 2026 ASN abstract reveal day. It should be a fun and meaningful experience. I am assuming 3-4 abstracts on Vafseo from akba and affilliates, maybe 1-2 abstracts on Vafseo on other applications not affiliated with akba and 1-2 abstracts on non Vafseo work by akba ie from ebri or prali. That will be a wholesome read and paves the way for akba's stock price to go much higher in the near, medium, and far term. Time is upon us, get ready for the ride up.

$AKBA It is sad to see what happens to a stock and drug with bad management and a corrupt FDA. This drug passed both DD and NDD studies. The FDA CRLed both because both were submitted together. Thanks JB! They finally allowed DD after a large delay and resubmital. NDD excuses by the FDA were all blatant lies. Now the Cohort study proves NDD stages 4&5 patients benefit from V by reducing all-cause mortality. How can this incredible benefit be ignored unless crooked incompetent people at the FDA are undermining the drug! TDAPA didn’t help anything because the two largest DO’s are not using it. DaVida’s 275k is in play, but with no known rampup data, here we are. DaVita’s top down push based on the Voice and Vocal studies are the catalyst that we are waiting for. We should get some news during Q3 ER. KCAPA passage and TDAPA extension are still on the table with a TDAPA extension possible anytime. Hopefully we will get some DaVita news to celebrate at Q3 ER.

$AKBA so final tally for ASN: 1 Late breaking abstract (LBA) at the most prime and longest 15 min time slot for Dr Block to present the voice results at. Also 7 abstracts, 6 on akba PR site and affiliated with them, the other abstract is from NYMC in ESA for anemia in CKD. The 6 affiliated with akba are 3 Vafseo abstracts, 2 prali ones and 1 ebri one. Very strong abstracts all around and should generate plenty of good buzz at ASN for akba. Akba is doing all things right, it is a shame the stock price does not reflect the same optimism. Eventually (and I think real soon) big pharma will come sniffing at akba for buyout reasons. Too much novelty and money involved to not have that happen. The only question in my mind is that is the BO offer strong enough for Butler to accept? I still say NO, regardless akba will be trading many multiples higher than what it is trading today. Stock price is absurdly low and it's being disrespected badly to being clubbed with other worthless bios.

$AKBA it’s really astounding how they’re pinning down the price. In essence, they are forcing mgmt to deliver some revenue guidance! Without it, price will probably not move significantly. Butler is going to have to do something or his ass will soon get finally fired! Even as complicit as the board is, they’re going to have to something soon!

$AKBA GM! Two new KCAPA co-sponsors. Neal Dunn is a big one. He is on Energy and Commerce and the subcommittee’s vice chair. The Sept 15 hearing was in that committee. A vice chair signing on is a better signal than another back bencher. He was not a cosponsor when the hearing happened. Let's keep it going! H.R.6214 - Kidney Care Access Protection Act (119th Congress) Sponsor: Rep. Miller, Carol D. [R-WV-1] (Introduced 11/20/2025) Has changes in: Cosponsors (2 new, 18 total) Cosponsor: 10/09/2026: Rep. Dunn, Neal P. [R-FL-2] Cosponsor: 10/09/2026: Rep. Thanedar, Shri [D-MI-13]

$AKBA I’m upset seeing stock price not going to lie. My only explanation is vafseo can’t be modelled because no one knows what the post TDAPA pricing will be. We know it will be “ESA like” but no one knows the price LDOs pay for their ESA, nor do they know what criteria is met to reach it. As a result the market has no ability to apply any forward looking metrics. We also don’t know the true cost of manufacturing vafseo as they have been using pre CRL inventory previously tagged as R&D spending. lastly no idea on if Davita will utilize in meaningful quantity. Algos can not appropriately price anything and so it looks at decreasing revenues and even lower projections next year and the machines take us behind the woodshed. This valuation remain decoupled from reality, and vafseo as an asset remains much more valuable than the balance sheet suggests, especially to the right company. We must wait for these unknowns to become known in the next 2 years then maybe the insanity will end.

$AKBA This is a chart of John Butler's annual compensation versus year end AKBA stock price since he took over as CEO. His total comp over this period is $55.3 million and the AKBA stock price has a total return of -95.47%. Honestly, I can't blaim him as he has absolutely taken advantage of the game. But the Board of Directors, on the other hand...what a joke. How do you reward this type of performance? I don't do social media, but if someone wanted to paste this all over the Akebia pages, that would be great. They need to be put on blast.

$AKBA Let’s see what the new generation has to offer at Fresenius. Not only Shervan J. Korangy (51), who is open to innovation and is set to become CEO, but also Cassie McLean (48), who worked at Davita for 16 years and is now CEO of Care and Delivery. This could bring about a major turnaround. An Custin, who holds a key role on the executive board, is also known for her innovative ideas. I think this is a promising and interesting development. Glta!

$AKBA I GIVE UP. I’M SELLING. The hedgies, market makers, tutes, as well as the toady bears, flippers, shorts, trolls who work for them are just too strong. $.80 must be the true value of Akebia’s approved and marketed drugs, its pipeline, and cash for operations, as well as brick and mortar assets. JUST KIDDING. F*CK HARD THE FOREGOING SCUMBAGS. HOLDING LONG.

$AKBA Just wanted to clarify that although I have been posting bearish lately, I’m just venting my frustration with the price…I haven’t sold a single share and don’t plan to until double digits which I wholeheartedly believe will happen…Good luck to us all…forever an Akebian Bull…hmmm💎

$AKBA All the FUDsters crawled out from dark places. The company is undervalued PERIOD. Added 5 K today.

$AKBA I honestly struggle to understand AKBA’s valuation at $0.82. Vafseo has shown encouraging advantages over ESAs, yet adoption remains surprisingly slow. Meanwhile, the market seems to price in every possible negative while assigning almost no value to positive VOICE results, potential DaVita expansion, upcoming VOCAL data, KCAPA, the possibility of Fresenius entering the market, or Akebia’s entire pipeline. I understand the post-TDAPA risks, but are we seriously saying none of these opportunities has any value? It feels like the market is pricing in only the risks it wants to see while ignoring everything else.

$AKBA Do you know what a good Board of Directors would do? At these beaten-down prices, I’d expect every single director to put $100K of their own money into the stock—show shareholders they actually believe in the company. Then, if the balance sheet allows it, initiate an opportunistic $50M buyback while the stock is severely undervalued. Provide real quarterly shareholder presentations with transparency on strategy, capital allocation, Vafseo adoption, the pipeline, and measurable milestones. But instead, what do we get? More dilution. Executive compensation and bonuses. Golden-parachute protections. And presentations that often feel more focused on protecting management than creating value for shareholders. I honestly can’t remember seeing a Board where the interests of shareholders seem this far down the priority list. The Board’s job should be simple: maximize long-term shareholder value while responsibly guiding the company—not protect management and their seats for more $

$AKBA Low volume. Triggers were hit. Should bounce towards closing. Just the BS corrupt market at work.

$AKBA I’m back in ; cannot ignore 85 cents a share lol !!!! I have a love and hate relationship with this one !!!! Good morning bulls ; when $3

$AKBA ill take a stab @ that million dollar question. HIF-PHI science is gonna be “BiG” and they fukin know it.

$AKBA Constantly trading accusations back and forth (between bulls and bears) is a waste of energy. We need to move forward! Let’s see what Q3 and Q4 bring. We need to reach 50,000 patients in the U.S. by Q1 2027 to break even. Before, the focus was on the product’s effectiveness and dosage; that’s behind us now. It’s all about when we’ll get there—no more words are needed!

$AKBA Chasing Mr. Pithy's share count one dip at a time. Still bullish on AKBA and ready for that quick turnaround!